Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia

Iria Fernandez Botana; Giulia Pagano; Etienne Moussay; Jerome Paggetti

doi:10.1080/2162402X.2023.2276490

Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia

Oncoimmunology. 2023 Nov 3;12(1):2276490. doi: 10.1080/2162402X.2023.2276490. eCollection 2023.

Authors

Iria Fernandez Botana^{1

2}, Giulia Pagano^{1

2}, Etienne Moussay¹, Jerome Paggetti¹

Affiliations

¹ Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg.
² Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighting its suitability for immune-mediated therapeutic interventions. We recently revealed that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell-mediated mechanism.

Keywords: CD8+ T cells; Cytokine; IL-27; immunotherapy; leukemia.

MeSH terms

Adult
Cytokines
Humans
Immunosuppression Therapy
Interleukin-27*
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
T-Lymphocytes

Substances

Interleukin-27
Cytokines

Grants and funding

This work was supported by grants from the Luxembourg National Research Fund (FNR) and Fondation Cancer, Luxembourg to EM and JP (C20/BM/14582635 and C20/BM/14592342) and from Fonds National de la Recherche Scientifique (FNRS)-Télévie to IFB and GP (7.4501.18, 7.4529.19, 7.6518.20, and 7.6603.21).